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Abstract
Identifying novel neuroprotectants that can halt or reverse the neurological effects of stroke is of interest to both clinicians and
scientists. We and others previously showed the pre-clinical neuroprotective efficacy of neuregulin-1 (NRG-1) in rats following
focal brain ischemia. In this study, we examined neuroprotection by exogenous and endogenous NRG-1 using a mouse model of
ischemic stroke. C57BL6 mice were subjected to middle cerebral artery occlusion (MCAO) followed by reperfusion. NRG-1 or
vehicle was infused intra-arterially (i.a.) or intravenously (i.v.) after MCAO and before the onset of reperfusion. NRG-1 treatment
(16 μg/kg; i.a.) reduced cerebral cortical infarct volume by 72% in mice when delivered post-ischemia. NRG-1 also inhibited
neuronal injury as measured by Fluoro Jade B labeling and rescued NeuN immunoreactivity in neurons. Neuroprotection by
NRG-1 was also observed in mice when administered i.v. (100 μg/kg) in both male and female mice. We investigated whether
endogenous NRG-1 was neuroprotective using male and female heterozygous NRG-1 knockout mice (NRG-1+/−) compared
with wild-type mice (WT) littermates. NRG-1+/− and WT mice were subjected to MCAO for 45 min, and infarct size was
measured 24 h following MCAO. NRG-1+/− mice displayed a sixfold increase in cortical infarct size compared with WT mice.
These results demonstrate that NRG-1 treatment mitigates neuronal damage following cerebral ischemia. We further showed that
reduced endogenous NRG-1 results in exacerbated neuronal injury in vivo. These findings suggest that NRG-1 represents a
promising therapy to treat stroke in human patients.
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Introduction
Stroke remains a leading cause of death in the USA and the
most frequent cause of long-term disability. Ischemic stroke
occurs as a result of an obstruction within a blood vessel
supplying blood to the brain. The neuronal death that ensues
results from the induction of genes and the activation of path-
ways associated with a number of cellular functions including
apoptosis, inflammation, and oxidative stress (Iadecola and
Anrather 2011). Currently, the tissue plasminogen activator
(t-PA) is the only approved drug treatment for ischemic stroke.
Unfortunately, t-PA has a limited time window for therapeutic
use, and only 3–5% of stroke patients arriving at the hospital
will qualify for treatment (Fisher et al. 2009). Thus, there is a
strong need to understand the molecular mechanisms associ-
ated with ischemic stroke so that more effective modes of
treatment can be investigated.
Multiple neuroprotective compounds have been reported to
be effective against cerebral ischemia in animal and cell
models, but none of these drugs were shown to be clinically
effective (Bosetti et al. 2017; Fisher et al. 2009; Saver et al.
2009; Savitz and Fisher 2007). Neuregulins have been impli-
cated in normal brain function, as well as in neuroprotection
following cerebral ischemia. Previous studies from our labo-
ratory and others demonstrated that neuregulin-1 (NRG-1)
reduced ischemia-induced neuronal death in a rat focal stroke
model by ~ 90% with a therapeutic window of > 13 h (Guo
et al. 2006; Li et al. 2007; Shyu et al. 2004; Wang et al. 2015,
2018; Xu et al. 2004, 2005, 2006). NRG-1 administration also
resulted in a significant improvement of neurological function
(Iaci et al. 2010; Xu et al. 2006). NRG-1 administration
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resulted in a significant improvement of neurological function
when administered 3 days following ischemia, suggesting a
role in neuronal repair (Iaci et al. 2010, 2016). Recent clinical
studies demonstrated the utility of NRG-1 in human patients
(Gao et al. 2010; Jabbour et al. 2011; Lenihan et al. 2016)
(C l i n i c a lTr i a l s . gov iden t i f i e r s NCT01258387 ;
NCT01251406). Systemic administration of NRG-1 im-
proved cardiac function in heart failure patients. The doses
used in these clinical trials were comparable to the effective
dose in stroke models; thus, NRG-1 has potential therapeutic
value in treating individuals after acute ischemic stroke in
clinical studies.
In this study, we examined the neuroprotective efficacy of
exogenous and endogenous NRG-1 on cerebral injury after
the induction of ischemia by middle cerebral artery occlusion
(MCAO) in mice. NRG-1 homozygous knockout mice are
embryonic lethal at embryonic day 10.5. However, heterozy-
gous knockout mice lacking one functional copy of the gene
for NRG-1 (NRG-1+/−) express reduced levels of brain NRG-
1 (Erickson et al. 1997; Gerlai et al. 2000; Sandrock et al.
1997) and display hyperactive and schizophrenia-like pheno-
types during neurobehavioral testing (O'Tuathaigh et al. 2007,
2008, 2010; Stefansson et al. 2002). We demonstrated that
exogenously administered NRG-1-protected neurons from ce-
rebral ischemia in both male and female mice. In addition,
NRG-1+/− mice displayed significantly larger infarcts than
wild-type littermates, suggesting a neuroprotective role for
endogenous NRG-1. Our data demonstrate that NRG-1 is a
potent neuroprotectant against ischemic brain injury with high
clinical potential. These findings may aid in identifying a nov-
el therapeutic strategy for the treatment of stroke.
Materials and Methods
Animals All animals used in these studies were treated hu-
manely and with regard for alleviation of suffering and pain,
and all protocols involving animals were approved by the
IACUC of Morehouse School of Medicine and University of
California-Riverside prior to the initiation of experimentation.
Male and female C57BL6 mice (8–10 weeks old) were pur-
chased from Charles River (Wilmington, MA) and housed
with a 12-h daily light/dark cycle.Male and female (10months
old) NRG-1 heterozygous transgenic mice (NRG-1+/−) and
wild-type littermates (WT; NRG-1+/+) were also used in this
study (Meyer and Birchmeier 1995). The NRG-1 gene knock-
out mouse was generated by deletion of exons 7, 8, and 9,
which encode the carboxy terminal of the EGF domain of all
known NRG-1 isoforms. Mice with homozygous knockout of
NRG-1 (NRG-1−/−) are embryonic lethal. However, the
NRG-1+/− mice display reduced brain NRG-1 levels which
are viable but display some abnormal neurobehavioral func-
tions (Erickson et al. 1997; Gerlai et al. 2000; Sandrock et al.
1997; Stefansson et al. 2002). Food and water were provided
ad libitum. All surgical procedures were performed by sterile/
aseptic techniques in accordance with institutional guidelines.
Transient Middle Cerebral Artery Occlusion Animals were
subjected to left MCA occlusion (MCAO). Mice were anes-
thetized with 1.5% isoflurane in 68.5% N2O and 30% O2.
MCA occlusion was induced by the intraluminal suture tran-
sient MCAO method as previously described (Barber et al.
2004). The left common carotid artery (CCA) was exposed
through a midline incision and was carefully dissected free
from surrounding nerves and fascia. The occipital artery
branches of the external carotid artery (ECA) were then iso-
lated, and the occipital artery and superior thyroid artery
branches of the ECAwere coagulated. The ECAwas dissected
further distally. The internal carotid artery (ICA) was isolated
and carefully separated from the adjacent vagus nerve, and the
pterygopalatine artery was ligated close to its origin with a 6–0
silk suture. Then, a 12-mm 7–0 surgical monofilament nylon
suture with rubber silicon (Doccol, Sharon, MA) was inserted
from the external carotid artery (ECA) into the internal carotid
artery (ICA) then into the circle of Willis to occlude the origin
of the left middle cerebral artery. The nylon suture was with-
drawn 1 h following ischemia, and the brain tissues were
reperfused for 23 h before sacrifice. Mice within the intrave-
nous treatment group underwent filament occlusion for
90 min, and the brain tissues were reperfused for 22.5 h before
sacrifice because of variability in baseline infarct size between
male and female mice with 60 min of MCAO. Regional cere-
bral blood flow (CBF) was measured by continuous laser
Doppler flowmetry (LDF) with a laser Doppler probe
(Perimed, Kings Park, NY) placed in the ipsilateral skull close
to the middle cerebral artery from the beginning of theMCAO
surgery until 15 min after reperfusion. For NRG-1+/− (n = 6)
and WT (n = 6) knockout mice, MCAO occurred for 45 min
and the brains were reperfused for 23.25 h before sacrifice.
The 45-min time point was chosen so that infarction was sub-
maximal which allowed us to determine if infarcts grew larger
in the transgenic animals. The surgical procedure was consid-
ered successful if CBF was reduced by ≥ 70% immediately
after placement of the occluding suture; otherwise, mice were
excluded.
To determine the effects of NRG-1 on ischemic stroke,
mice were randomly divided into two treatment groups and
injected intra-arterially (i.a.) with either a single-bolus 5-μL
dose of vehicle (0.1% BSA in PBS) or NRG-1β (10 μmol/L
NRG-1 (EGF-like domain, R&D Systems, Minneapolis, MN)
in 1% BSA in PBS) through a Hamilton syringe as previously
described (Xu et al. 2004, 2005, 2006). This resulted in the
administration of 16 μg of NRG-1/kg body weight. NRG-1
(n = 9) or vehicle (PBS; n = 9) was administered by bolus
injection into the ICA through the ECA immediately before
reperfusion. A second group of female (n = 6) andmale (n = 4)
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mice were injected intravenously (i.v.) into the tail vein with
either a single-bolus 100-μL dose of vehicle (0.1% BSA in
PBS) or NRG-1β (100 μg/kg) with a 30-G needle immediate-
ly after filament insertion. All NRG-1 and vehicle treatment
studies were performed in a blinded manner. Core body tem-
perature was closely monitored with a rectal probe and main-
tained at 36.1 ± 0.1 °C with a Homeothermic Blanket Control
Unit (Harvard Apparatus, Holliston, MA) during anesthesia to
prevent hyperthermia as a confounding factor (Barber et al.
2004).
Infarct Size Measurement and Neurobehavioral Testing
Twenty-four hours after MCAO, 1.0- or 2.0-mm-thick brain
sections were stained with 2–5% triphenyltetrazolium chlo-
ride (TTC) solution and then transferred into a 4% formalde-
hyde solution for fixation. The infarcted region appears white,
whereas the normal non-infarcted tissue appears red. The in-
farct area was identified by using five to seven slices of coro-
nal sections from each brain. The infarct area was calculated in
a blinded manner by capturing the images with a digital cam-
era. Percentages of cortical and striatal infarct were calculated
as a percentage of cortical and striatal volume, respectively
(percentage of total infarct = infarct volume/(hemispheric vol-
ume) × 100%.). Infarct volumes were analyzed by t test;
p < 0.05 was regarded as significant. Mice were assessed for
neurobehavioral deficits 24 h after MCAO. The neurobehav-
ioral score evaluation system is as follows: 0, normal; 1, con-
sistent forelimb and axial flexion toward the contralateral to
the lesion side when lifted by the tail; 2, observations of score
1 with consistently reduced resistance to lateral push and gait
toward the paretic side; 3, observations of score 2 plus large or
weak circling toward the paretic side; and 4, score 2 plus
circling toward the paretic side (Barber et al. 2004).
Histology and Immunohistochemistry After MCAO, mice
were deeply anesthetized with 2% isoflurane and perfused
transcardially with saline followed by cold 4% paraformalde-
hyde (PFA) solution in PBS for 30 min (n = 4–5 animals/
group). Brains were quickly removed and cryoprotected in
30% sucrose. The brains were then frozen in OCT compound
and stored at − 80 °C until sectioning. Coronal sections of 10–
20-μm thickness were cryosectioned and mounted on slides
which were then stored at − 80 °C until further processed.
Fluoro Jade B (FJB; AG310, Millipore, Billerica, MA) label-
ing was performed according to the manufacturer’s protocol
with minor modifications. Briefly, after 30 min drying at
50 °C, sections were post-fixed with 4% paraformaldehyde
for 15 min, washed with distilled water, and then directly
incubated in 0.06% potassium permanganate (KMnO4) for
10 min on a shaker table followed by distilled water for
2 min. Sections were then incubated in a freshly prepared
solution of 0.0004% FJB for 20 min, rinsed in distilled water,
and then dried at 50 °C. Dried slides were cleared by
immersion in xylene for 2 min before cover slipping with
DPX mounting medium.
TUNEL labeling was performed using the in situ death
detection kit from Roche Molecular Biochemicals
(Indianapolis, IN). Briefly, sections were incubated in
20 μg/ml proteinase K solution for 10 min at room tempera-
ture to increase permeability. After 2 washes in PBS, sections
were immersed in the TUNEL reaction mixture, containing
biotinylated dUTP and terminal deoxynucleotidyl transferase
(TdT) conjugated with fluorochrome tetramethyl rhodamine
red for 60 min at 37 °C in a dark, humidified atmosphere. The
process was terminated by washing sections twice with a
blocking buffer (PBS, 0.1% Triton X-100, and 5 mg/mL
BSA). In each assay, negative controls were included using
the same incubation procedure but omitting TdT in the pro-
cess, whereas positive controls were performed by incubating
the permeated sections with DNase (1 μg/mL) to induce DNA
strand breakage.
For immunohistochemical studies, sections were dried at
room temperature for 30 min. After rinsing with 0.01 M PBS,
sections were blocked in PBS containing 5% normal goat
serum and 0.3% Triton X-100 for 1 h at 4 °C and then incu-
bated overnight at 37 °C with primary antibodies of monoclo-
nal mouse anti-NeuN (1:200, MAB314, Millipore, Billerica,
MA). Sections were washed with PBS and incubated with a
FITC-conjugated goat anti-mouse IgG antibody (1:400,
Cat#115-095-146, Jackson ImmunoResearch Laboratory,
West Grove, PA) for 1 h at room temperature. A Zeiss micro-
scope equippedwith a CCD camera (Carl Zeiss Microimaging
Inc., Thornwood, NY) was used to capture all digital images
of sections at ×20 magnification.
Quantification FJB- and NeuN-Immunopositive Cells The
number of FJB- and NeuN-positive cells was determined
using Image Pro Plus and ImageJ software (Media
Cybernetics, Inc., Bethesda, MD) by an individual who was
blinded to the experimental treatments. Only normal morpho-
logical profiles of NeuN-positive cells were counted, and
shrunkenNeuN-positive signals were excluded. Amean value
of FJB-positive or NeuN cells per unit area from five brain
sections within the brain regions was obtained for each indi-
vidual mouse brain. Data were expressed as mean ± SEM.
These mean values from each individual mouse were used
as the statistical unit of measure for analysis by t test to deter-
mine statistically significant treatment effects.
Results
NRG-1 Protects Against Ischemia-Induced Brain InjuryWe ex-
amined the neuroprotective effects of NRG-1 following
MCAO in mice. NRG-1 was administered immediately after
reperfusion. Brain tissues were analyzed in mice treated with
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NRG-1 or vehicle i.a. immediately after reperfusion and
sacrificed 24 h after MCAO. Figure 1a illustrates a typical
TTC staining of brain sections treated with vehicle or NRG-
1 after MCAO. Compared with controls, i.a. administration of
NRG-1 drastically reduced infarct volume after MCAO in
mice as we and others previously showed in rats (Guo et al.
2006; Li et al. 2007; Shyu et al. 2004; Wang et al. 2015, 2018;
Xu et al. 2004, 2005, 2006). The percentage of total infarct
volume to the ipsilateral hemisphere in vehicle-treated ani-
mals was 41%. NRG-1 significantly reduced the total infarct
volume to 15% of hemispheric volume representing a 67%
reduction in infarct size (from 78.9 to 25.6 mm3) (Fig. 1b).
The relative reduction in cortical and subcortical neuronal
injury was also calculated. The infarct volume of control an-
imals represented 56% of the total size of the ipsilateral cortex.
Treatment with NRG-1 resulted in an infarct that was reduced
to 16% of the ipsilateral cortex, which corresponds to a 72%
reduction in cortical infarct size (from 53.0 to 15.0 mm3)
(Fig. 1c). NRG-1 treatment reduced infarction by 50% in sub-
cortical regions (Fig. 1d). Regional CBF was measured by
LDF for each mouse during MCAO and after reperfusion.
NRG-1 did not significantly affect the CBF reduction after
MCAO (p = 0.8695) or recovery after reperfusion (p =
0.8722) (Fig. 2; n = 9 in each group). NRG-1 also did not
affect the baseline body temperature, body temperature 24 h
post-MCAO, or body weight loss (Fig. 3). No significant dif-
ference in neurological outcome was observed between con-
trols and NRG-1-treated animals at this time point (data not
shown).
NRG-1 Blocks Ischemia-Induced Neuronal Death Neuronal in-
jury and the neuroprotective effects of NRG-1 treatment were
also assessed by FJB staining. Brain tissues from mice treated
with either NRG-1 or vehicle were examined 24 h after
MCAO/reperfusion, and extensive FJB staining was found
within the ischemic cortical and subcortical regions (Fig. 4).
Ischemia-induced FJB staining was reduced by 64% NRG-1
treatment in the areas within the cerebral cortex. NRG-1 also
dramatically reduced TUNEL labeling after MCAO (Fig. 5).
MCAO reduced NeuN immunoreactivity in cortical neurons
(Fig. 6). These injured areas showed high numbers of FJB
labeling in adjacent sections as seen in Fig. 4. Neighboring
neurons that were not injured showed relatively higher levels
of NeuN immunoreactivity. NRG-1 post-treatment rescued
NeuN immunoreactivity following MCAO.
Neuroprotection was observed following i.v. administra-
tion of NRG-1 in male and female mice (Fig. 7a, b).
Vehicle-treated mice exhibited an average total infarct volume
of 24.9% and NRG-1 reduced that percentage to 13.3%, a
46.6% reduction (Fig. 7c; 2 males + 3 females per treatment
group). Vehicle-treated mice resulted in an average cortical
infarct volume of 26.8% that NRG-1 significantly reduced to
an average of 7.5%, a 72.1% reduction specifically within the
ipsilateral cortex. No difference in lesion size was seen within
the ipsilateral subcortical region.
Endogenous NRG-1 Protects Neurons from Ischemic Injury To
determine if endogenous NRG-1 is involved in ischemic brain
injury, we examined cerebral infarction in male and female (3
Fig. 1 NRG-1 reduced infarct volume following MCAO/reperfusion.
Mice were treated with NRG-1 (16 μg/kg) or vehicle immediately after
MCAO followed by 23 h of reperfusion. Brains were removed, sliced into
seven coronal sections (1 mm thick), and treated with 2% TTC (a). NRG-
1 reduced total infarct volume by 67% (b; p < 0.0001). Treatment with
NRG-1 resulted in a 72% reduction in cortical infarct size (c; p < 0.0001)
and 50% in subcortical regions (d; p = 0.001). N = 9 mice per treatment
group
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males and 3 females per group) NRG-1+/− mice and WT
littermates. MCAO was performed for 45 min rather than
1 h to produce smaller, submaximal infarcts and examine
whether reduced endogenous NRG-1 could result in increased
neuronal damage. There was no difference in CBF reductions
and recovery between WT and NRG-1+/− mice (Fig. 8a, b);
however, the infarct volume in the cerebral cortex of NRG-1+/
− mice was sixfold larger than that observed in WT mice
(Fig. 8c–f). However, there was no difference in subcortical
infarct volume between the two groups and thus total hemi-
sphere infarct volume was not statistically significant when
compared.
Discussion
NRG-1 belongs to a family ofmultipotent neuroprotective and
anti-inflammatory growth factors that include acetylcholine
receptor–inducing activities (ARIAs), glial growth factors
(GGFs), heregulins, and neu differentiation factors (NDFs)
(Falls et al. 1993; Ho et al. 1995; Holmes et al. 1992;
Marchionni et al. 1993; Wen et al. 1992). We have shown that
NRG-1 reduced ischemic brain injury when administered ei-
ther before or 13.5 h after MCAO (Xu et al. 2006). NRG-1 has
also been shown to promote functional recovery in a rat stroke
model when administered intravenously up to 7 days after
ischemia (Iaci et al. 2010). In this study, we examined if ex-
ogenously applied or endogenous NRG-1 was neuroprotec-
tive in a mouse MCAO model. We observed that both i.a. and
i.v. administration of NRG-1 reduced neuronal injury in mice.
The neurobehavioral test we used to examine the acute effects
of ischemic stroke and NRG-1 did not correlate with the his-
tological protection as we observed in the rat stroke model
(Xu et al. 2004, 2006). Future studies will employ more sen-
sitive tests to examine the long-term neurobehavioral conse-
quences of NRG-1 treatment following ischemia in mice be-
yond the 24-h time point.
We also observed that ischemic brain injury was more se-
vere in NRG-1+/− knockout mice compared with WT mice
suggesting that endogenously expressed NRG-1 is involved in
Fig. 3 NRG-1 does not affect
animal body temperature weight.
NRG-1 or vehicle was
administered immediately after
reperfusion. There was no
statistical significance between
vehicle and NRG-1-treated
animals for the baseline body
temperature (a; p = 0.8020); body
temperature 24 h post-MCAO (b;
p = 0.5944), or body weight loss
(c; p = 0.5584) (n = 9 in each
group)
Fig. 2 NRG-1 does not affect
regional CBF. Regional CBF was
measured by LDF for each mouse
during MCAO and after
reperfusion. NRG-1 did not
significantly affect the CBF
reduction after MCAO (a; p =
0.8695) or recovery after
reperfusion (b; p = 0.8722) (n = 9
in each group)
J Mol Neurosci
the function of neurons under normal conditions. NRG-1−/−
homozygous knockout mice die in utero, but heterozygous
NRG-1+/− mice are viable and with reduced amounts of
NRG-1 in the brain (Erickson et al. 1997; Gerlai et al. 2000;
Sandrock et al. et al. 1997; Stefansson et al. 2002).
Heterozygous NRG-1 knockout mice were shown to have a
“schizophrenia-like” phenotype including alterations in pre-
pulse inhibition and anxiety-like behaviors (Erickson et al.
1997; Gerlai et al. 2000; O'Tuathaigh et al. 2007, 2008,
2010; Sandrock et al. 1997; Stefansson et al. 2002).
Polymorphisms in the NRG-1 gene have also been associated
with increased risk for schizophrenia in human patients
(Stefansson et al. 2002, 2004). Similar results were shown
w i t h e r bB4 knockou t m i c e f o l l ow i ng s t r ok e .
Neuroprotection by NRG-1 against cerebral ischemia was
prevented in the mice with erbB4 deleted in parvalbumin
(PV)-positive interneurons (Guan et al. 2015).
An important finding in this study is that NRG-1 was neu-
roprotective in both male and female mice. Pre-menopausal
women are protected from ischemic stroke compared with
males (Murphy et al. 2004). However, this neuroprotective
capacity is lost in post-menopausal women, where estrogen
levels reduced. Experimental studies have shown that pre-
menopausal female rodents and non-human primates were
protected from ischemia-induced brain injury compared with
males (Alkayed et al. 1998; Murphy et al. 2004, 2008; Toung
Fig. 4 NRG-1 reduced FJB
staining in the brain following
MCAO/reperfusion. Brains from
mice treated with either vehicle or
NRG-1 were examined 24 h after
MCAO/reperfusion. Extensive
FJB staining was found in brain
tissues following ischemia (a).
Ischemia-induced FJB staining
was significantly reduced by
NRG-1 (b). Amean value of FJB-
positive or per unit area from five
brain sections within the brain
regions was obtained for each
individual mouse brain (c; p =
0.0001). Data are expressed as
mean ± SEM. Scale bar = 100 μm
Fig. 5 NRG-1 blocks ischemia-
induced apoptosis. Brains from
mice treated with either vehicle or
NRG-1 were examined 24 h after
MCAO/reperfusion using
TUNEL labeling. Extensive
TUNEL labeling was found
within the brain following
ischemia (a). Ischemia-induced
TUNEL labeling was blocked by
NRG-1 treatment in the areas
within the cerebral cortex (b).
Scale bar = 50 μm
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et al. 2004). The observation that the neuroprotective effect of
NRG-1 was gender-independent makes it a more attractive
clinical candidate for neuroprotective therapy.
The STAIR report produced in response to the multiple
failed stroke neuroprotection clinical trials suggested that
pre-clinical stroke studies be performed in multiple species.
Fig. 6 NRG-1 protects neurons




in cortical neurons (a). NRG-1
treatment rescued NeuN
immunoreactivity (b, c; p =
0.0001). Scale bar = 100 μm
Fig. 7 NRG-1 reduced infarct volume via intravenous administration in
male and female mice. a Vehicle or b NRG-1 (100 μg/kg) was
administered immediately after filament insertion. MCAO occurred for
90 min followed by 23 h of reperfusion. Brains were removed, sliced into
five coronal sections (2 mm thick), and treated with 2% TTC. c NRG-1
reduced total infarct volume by 46.6% (b; p < 0.05). Treatment with
NRG-1 resulted in a 72.1% reduction in cortical infarct size (c;
p < 0.05) and no significant difference in subcortical regions. N = 5
mice (2 males + 3 females) per treatment group
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Therefore, it is clinically significant that NRG-1 is equally
neuroprotective in both mice and rats. Recently, we developed
a novel, minimally invasive ischemic stroke model with
young male rhesus macaques (Rodriguez-Mercado et al.
2012) which has been replicated with similar results in aged
female monkeys (Zhang et al. 2015; Li et al. 2018). This
procedure reliably produced infarcts and resulted in discrete
and limited neurobehavioral deficits, indicating the potential
of this stroke model for chronic neuroprotection studies in the
future. Therefore, in future studies we will be able to directly
examine the neuroprotective capacity of NRG-1 following
stroke in males and female non-human primate stroke models.
Thrombolysis is the only approved therapy for acute ische-
mic stroke and can be only be used in a limited patient popu-
lation. The present study demonstrates that NRG-1 is a viable
candidate neuroprotectant to treat acute ischemic stroke.
NRG-1 (Neucardin; Zensun Biotechnology, Shanghai,
China) is currently in phase III human clinical trials for the
treatment of heart failure and showed significant efficacy for
improving cardiac function in phase II patient studies in China
(Chinese Clinical Trial: ChiCTR-TRC-00000414) and
Australia (Australian New Zealand Clinical Trials Registry:
ACTRN12607000330448). Three additional clinical trials to
determine the ability of NRG-1 to improve cardiac function
after heart failure have been initiated in the USA
(C l i n i c a lTr i a l s . gov iden t i f i e r s NCT01258387 ;
NCT01541202; NCT01251406). These clinical studies
demonstrated that NRG-1 significantly improved heart func-
tion in patients and the effective doses were shown to be safe
and tolerable (Gao et al. 2010; Jabbour et al. 2011). This
suggests rationale for future clinical adjunctive treatment with
NRG-1 and tPA or endovascular thrombectomy. We recently
developed a partnership with Zensun to pursue FDA approval
to use Neucardin in clinical trials for stroke treatment (https://
news.ucr.edu/articles/2019/05/09/hope-horizon-treating-
stroke).
Recent studies showed that erbB4 prevented neuronal in-
jury and improved blood-brain barrier integrity in animal
models of subarachnoid hemorrhage (Qian et al. 2018; Yan
et al. 2017). This suggests that NRG-1 would not induce
F ig . 8 Endogenous NRG-1 pro tec t s neurons fo l lowing
MCAO/reperfusion. NRG-1+/− mice and WT littermates were
subjected to 45 min MCAO followed by 23.25 h of reperfusion. There
was no difference in CBF reduction (a, p = 0.3494) or recovery (b, p =
0.1645) between WT and NRG+/− mice. TTC labeling was used to
measure brain infarction in WT (c) and NRG-1+/− mice (d). There was
no difference in subcortical infarct volume between the two groups (not
shown), and thus, total hemisphere infarct volume was not statistically
significant when compared (e; p = 0.0549). However, the infarct volume
in the cerebral cortex of NRG-1+/− mice was 6-fold larger than that
observed in WT mice (f; p = 0.0406) N = 6 per experimental group
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hemorrhagic transformation after ischemia and could protect
patients from tPA-mediated toxicity. These findings could
support the development of clinical studies using NRG-1
alone or in conjunction with other therapies for the treatment
of patients with acute ischemic stroke.
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